Silence Therapeutics (SLN) Stock Statistics & Valuation Metrics

Silence Therapeutics has a market cap or net worth of $648.22M. The enterprise value is $446.72.

Silence Therapeutics has 47,246,677 shares outstanding. The number of shares has decreased by -2.65% in one year.

Silence Therapeutics’s return on equity (ROE) is -1.42 and return on invested capital (ROIC) is -76.11%.

The current PE Ratio of Silence Therapeutics is ―. Silence Therapeutics’s PEG ratio is 0.16.

In the last 12 months, Silence Therapeutics had revenue of 559.00K and earned -88.61M in profits. Earnings per share was -1.89.

In the last 12 months, operating cash flow was -42.29M and capital expenditures -58.00K, giving a free cash flow of -42.34M billion.

Silence Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Silence Therapeutics upcoming earnings date is Nov 17, 2026, Before Open (Confirmed).

Silence Therapeutics as a current ratio of 8.72, with Debt / Equity ratio of -0.29%

In the past 12 months, Silence Therapeutics has paid 11.00K in taxes.

Silence Therapeutics EV to EBITDA ratio is -3.14, with an EV/FCF ratio of -4.43.

Silence Therapeutics has $72.05M in cash and marketable securities with -$112.00K in debt, giving a net cash position of $72.17M billion.

Gross margin is 51.00%, with operating margin of -16055.99%, and net profit margin of -15851.88%.

The average price target for Silence Therapeutics is $34.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy